IPOGrid
0001610618
Company

Cidara Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · CDTX

follow-on priced Nasdaq EFFECT

Filing Timeline

SEC EDGAR
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2026-01-09 · 9999999995-26-000120
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2026-01-09 · 9999999995-26-000121
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2026-01-09 · 9999999995-26-000122
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2026-01-09 · 9999999995-26-000123
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2026-01-09 · 9999999995-26-000124
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2026-01-09 · 9999999995-26-000126
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $44.00 · Range $44.00 to $44.00 · 7,954,546 shares · Gross proceeds $350,000,024
Common Stock · Exchange Nasdaq · Ticker CDTX · Over-allotment 1,193,181 · Use of proceeds funding the ongoing development of CD388 · Underwriters J.P. Morgan, Morgan Stanley, Guggenheim Securities
2025-06-25 · 0001193125-25-147004
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2025-06-23 · 0001193125-25-144761
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2025-05-15 · 9999999995-25-001633
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2025-01-02 · 0001193125-25-000629
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
2024-12-31 · 9999999995-25-000020
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows EFFECT in the pre-IPO sequence.
2024-12-23 · 0001193125-24-284233
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
2024-07-31 · 0001193125-24-190044
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2024-07-31 · 9999999995-24-002342
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B5 in the pre-IPO sequence.
2024-07-19 · 0001193125-24-181693
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
Price $1.27 · 9,640,000 shares · Gross proceeds $12,213,880
Common Stock · Exchange Nasdaq Capital Market · Ticker CDTX · Over-allotment 1,446,000 · Use of proceeds to fund research and development activities for our development programs · Underwriters Cantor
2023-03-06 · 0001193125-23-061413
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2023-03-06 · 0001193125-23-061423
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2023-03-02 · 0001193125-23-058169
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2023-03-02 · 0001193125-23-058197
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2021-11-22 · 9999999995-21-004448
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2021-10-08 · 0001193125-21-295635
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2021-10-08 · 0001193125-21-295640
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2021-10-07 · 0001193125-21-294154
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2021-10-07 · 0001193125-21-294163
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2021-04-05 · 0001193125-21-105586
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2020-06-17 · 0001140361-20-014052
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2020-06-16 · 9999999995-20-001447
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2020-01-22 · 0001140361-20-001205
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2018-11-16 · 0001193125-18-328972
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2018-11-15 · 9999999995-18-002907
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows RW and confirms the priced prospectus.
2018-07-05 · 0001610618-18-000075
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2018-07-05 · 9999999995-18-001711
RW withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows 424B5 and ends the active registration process.
2018-06-05 · 0001610618-18-000057
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
2018-05-21 · 0001610618-18-000049
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2017-11-28 · 0001610618-17-000075
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B5 and marks the registration effective.
2017-11-27 · 9999999995-17-003066
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows 424B5 and confirms the priced prospectus.
2016-10-07 · 0001193125-16-733813
424B5 priced
Final prospectus supplement
Prospectus supplement filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2016-10-06 · 0001193125-16-732699
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B4 and marks the registration effective.
2016-06-01 · 9999999995-16-004801
424B4 priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2015-04-15 · 0001193125-15-131330
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 8-A12B and marks the registration effective.
2015-04-14 · 9999999995-15-000868
8-A12B effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
2015-04-09 · 0001193125-15-123816
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
2015-04-06 · 0001193125-15-119340
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
Common Stock · Exchange NASDAQ Global Market · Ticker CDTX · Underwriters Jefferies, Leerink Partners, Wedbush PacGrow Life Sciences
Cidara Therapeutics, Inc. is a biotechnology company focused on developing novel anti-infectives, including echinocandin-based therapies for fungal infections and a proprietary immunotherapy platform (Cloudbreak) for infectious diseases. The company is conducting an initial public offering (IPO) to raise up to $69 million through the sale of common stock, with shares expected to be listed on NASDAQ under the symbol CDTX. Key product candidates include CD101 IV (for systemic fungal infections) and CD101 topical (for recurrent vulvovaginal candidiasis), alongside Cloudbreak immunotherapy for invasive aspergillosis.
2015-03-13 · 0001193125-15-091277
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Cidara Therapeutics, Inc. is a biotechnology company focused on developing novel anti-infectives for serious fungal infections. The company is conducting its initial public offering (IPO) to raise capital for the development of its product candidates, including biafungin (a once-weekly IV echinocandin for systemic fungal infections) and topifungin (a topical antifungal for recurrent vulvovaginal candidiasis). Cidara is also advancing its Cloudbreak immunotherapy platform, which aims to harness the immune system to combat infectious diseases. The filing indicates the company is an emerging growth company under the JOBS Act, with plans to list on NASDAQ under the symbol 'CDTX'.
2015-02-04 · 0000950123-15-000837
Comparable Deals

10 comparable deals

Healthcare & Biotech$300M-1BLast 18 months
Only 0 strict matches; expanded to 10 using nearest neighbors.
Showing top 8 by similarity.
+3.9%
Median day-1
50%
Above issue
-1.3%
Median week-1
-35.3%
Downside (p10)
Eikon Therapeutics, Inc. EIKN
2026-02-05 $381M Day 1: -16.7% Wk 1: -19.5%
same SICsimilar deal sizerecent IPO
Agomab Therapeutics NV AGMB
2026-02-06 $200M Day 1: -8.4% Wk 1: -2.1%
same SICnearby deal sizerecent IPO
MapLight Therapeutics, Inc. MPLT
2025-10-27 $251M Day 1: +7.9% Wk 1: -0.5%
same SIC groupnearby deal sizerecent IPO
Evommune, Inc. EVMN
2025-11-06 $150M Day 1: +26.4% Wk 1: +22.0%
same SIC groupnearby deal sizerecent IPO
Aardvark Therapeutics, Inc. AARD
2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%
same SIC grouprecent IPO
Bicara Therapeutics Inc. BCAX
2024-09-13 $150M Day 1: +46.3% Wk 1: +53.8%
same SIC groupnearby deal sizeolder IPO
Veradermics, Inc MANE
2026-02-04 - Day 1: +11.0% Wk 1: +19.0%
same SIC grouprecent IPO
Caring Brands, Inc. CABR
2025-11-12 - Day 1: +0.0% Wk 1: -74.5%
same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.